| GORTEC 98-03 | Eine 2.-Bestrahlung verbessert das Ergebnis einer Chemotherapie von rezidivierenden, bestrahlten HNO-Tumoren oder 2. Tumoren nicht. | ||
| GORTEC2004-03 | IMRT | ||
| RTOG 79-13 (4) | Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality. | ||
| ARO 2005-3 | Wirksamkeit einer adjuvanten Strahlentherapie bei Patienten mit einem Plattenepithelkarzinom der Mundhöhle oder des Oropharynx und gesicherter solitärer ipsilateraler zervikaler Lymphknotenmetastasse (pN1). DÖSAK / ARO. Phase III | ||
| RTOG 83-13 (5,6) | Dose-response relationships for late radiation effects in the head and neck. | ||
| RTOG 90-03 (7) | Altered fractionation radiation for locally advanced head and neck cancer | ||
| PARSPORT | Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer. | ||
| AIO 1108 | Cetuximab, fluorouracil, cisplatin alone or with docetaxel for recurrent/metastatic head and neck cancer. | |
| GORTEC 2000-01 | Induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. | |
| RTOG 92 34 | Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer. | |
| ARO 2009-4 | Radiochemotherapie Stadien III, IV. Paclitaxel-Cisplatin (PACCIS-RCH) v. 5-FU-Cisplatin |
| Erlanger-Studie | Radiochemotherapie lokal fortgeschrittener Kopf-Hals-Tumoren |
| RTOG 01-29 | Acceleriert + Chemo v konventionell + Chemo: Ergebnis gleich. Phase III, 721 Pat. |
| ARO 95-06 | Hyperfraktionierte accelerierte Radiochemotherapie mit und ohne simultane FU-Mitomycin - Chemotherapie |
| GORTEC 99-02 | Acceleriert v Acceleriert + Chemo v konventionell + Chemo. Phase III, 840 Pat |
| ARO 2009-4 | PacCis-RCT Randomisierte Phase III Studie zur Radiochemotherapie lokal weit fortgeschrittener Kopf-Hals-Tumoren der Stadien III und IV A-B. Phase III. Fietkau, Erlangen |
| ARO 2014-1, ESCALOX | Haben die selektive Dosiseskalation der Strahlentherapie und der Tumorhypoxiestatus Einfluß auf die Lokalkontrolle von Kopf-Hals-Tumoren nach Radiochemotherapie? Phase III. Molls, München |
| SEQB | Zweiarmige randomisierte Phase-III Studie zur Wirksamkeit und Sicherheit einer Radiochemotherapie mit „Simultan Integriertem Boost (SIB) vs. „Sequentiellem Boost (SEQB)“ bei Patienten mit inoperablen lokal fortgeschrittenen Kopf-Hals-Tumoren. (Stromberger, Berlin) |
| EORTC 22931 | Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. |
| RTOG 05 22 | Concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma. |
| RTOG 99 14 | Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas |
| SAKK 10/94 | Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head-and-neck cancer |
| NRG-HV004 | durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin.(10) |
| EXTREME-Studie | Erbitux in first-line treatment of recurrent or metastastic head and neck cancer | |
| GORTEC 2006-01 | Sunitinib monotherapy in palliative squamous cell carcinoma of the head and neck | |
| GORTEC 2008-02 | figitumumab in recurrent or metastatic squamous cell carcinoma of the head and neck. | |
| CheckMate 141 | Nivolumab verbessert bei rezidivierten, fortgeschrittenen HNO - Plattenepithel - Karzinomen das Gesamtüberleben signifikant gegenüber einer Monochemotherapie bei deutlich weniger Nebenwirkungen! |
| CheckMate 651 | Nivolumab, Ipilimumab Versus EXTREME Regimen(6x cetuximab, cisplatin/carboplatin, 5-FU) as First-Line Treatment forRecurrent/Metastatic Squamous Cell Carcinoma |
| KEYNOTE-012 | Pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma |
| Keynote-040 | Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma(11) |
| Keynote-048 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(12) |
Teil von
Chemotherapy added to locoregional treatment for head and neck cancer squamous cell carcinoma: Three meta-analyses of updated individual data.
Lancet 355(2000):949–955
2.) Bourhis J, Armand C, Pignon JP:
Update of MACH-NC (Meta-Analysis of Chemotherapy in Head and Neck Cancer) database focused on concomitant chemoradiotherapy.
JCO 23(Suppl)(2004):488 (Abstract)
3.) Denis F, Garaud P, Bardet E, et al.:
Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
JCO 22(2004):69–76.
4.) Marcial VA, Pajak TF, Chang C, et al.:
Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary-report) by the Radiation Therapy Oncology Group (RTOG).
Int J Radiat Oncol Biol Phys 1987;13:41-47.
5.) Bentzen SM, Thames HD.:
Dose-response relationships for late radiation effects in the head and neck: Regarding the analysis of the RTOG 8313 trial, Fu et al. IJROBP 32:577-588; 1995.
Int J Radiat Oncol Biol Phys 1996;34:523-524.
6.) Cox JD, Pajak TF, Marcial VA, et al.:
Interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts dresults from Radiation-Therapy Oncology Group protocol 8313.
Int J Radiat Oncol Biol Phys 1991;20:1191-1195.
7.)Beitler JJ, Zhang Q, Fu KK, et al.:
Final results of local-regional control and late toxicity of RTOG 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer.
Int J Radiat Oncol Biol Phys 2014;89:13-20.
8.) Harrington K, et al.:
Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
J Clin Oncol 2015;33:4202-4209. DOI: 10.1200/JCO.2015.61.4370
9.) Gillison ML, Trotti AM, Harris J, et al.:
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial.
Lancet 2019;393:40-50
10.) Mell L K, et al.:
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
The Lancet Oncology 2024;25(12):1576-1588
11.) Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al.:
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Lancet. 2019;393(10167):156-67.
12.) Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., et al.:
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Lancet. 2019;394(10212):1915-28.
